Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

Autor: Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McCue D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burger J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abusab T; Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA., Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien S; Department of Medicine, UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep; Vol. 65 (9), pp. 1325-1334. Date of Electronic Publication: 2024 May 15.